Literature DB >> 25016054

Galleria mellonella native and analogue peptides Gm1 and ΔGm1. II) anti-bacterial and anti-endotoxic effects.

Wilmar Correa1, Marcela Manrique-Moreno2, Jochen Behrends3, Edwin Patiño4, Chakravarthy Marella5, Carlos Peláez-Jaramillo6, Patrick Garidel7, Thomas Gutsmann8, Klaus Brandenburg9, Lena Heinbockel10.   

Abstract

Antimicrobial peptides (AMPs) are important components of the innate immune system of animals, plants, fungi and bacteria and are recently under discussion as promising alternatives to conventional antibiotics. We have investigated two cecropin-like synthetic peptides, Gm1, which corresponds to the natural overall uncharged Galleria mellonella native peptide and ΔGm1, a modified overall positively charged Gm1 variant. We have analysed these peptides for their potential to inhibit the endotoxin-induced secretion of tumour necrosis factor-α (TNF-α) from human mononuclear cells. Furthermore, in a conventional microbiological assay, the ability of these peptides to inhibit the growth of the rough mutant bacteria Salmonella enterica Minnesota R60 and the polymyxin B-resistant Proteus mirabilis R45 was investigated and atomic force microscopy (AFM) measurements were performed to characterize the morphology of the bacteria treated by the two peptides. We have also studied their cytotoxic properties in a haemolysis assay to clarify potential toxic effects. Our data revealed for both peptides minor anti-inflammatory (anti-endotoxin) activity, but demonstrated antimicrobial activity with differences depending on the endotoxin composition of the respective bacteria. In accordance with the antimicrobial assay, AFM data revealed a stronger morphology change of the R45 bacteria than for the R60. Furthermore, Gm1 had a stronger effect on the bacteria than ΔGm1, leading to a different morphology regarding indentations and coalescing of bacterial structures. The findings verify the biophysical measurements with the peptides on model systems. Both peptides lack any haemolytic activity up to an amount of 100μg/ml, making them suitable as new anti-infective agents.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibacterial/antimicrobial peptide; Atomic force microscopy; Galleria mellonella; Lipopolysaccharide; Peptide-lipid interaction

Mesh:

Substances:

Year:  2014        PMID: 25016054     DOI: 10.1016/j.bbamem.2014.07.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Virulence of the Pathogen Porphyromonas gingivalis Is Controlled by the CRISPR-Cas Protein Cas3.

Authors:  Jose Solbiati; Ana Duran-Pinedo; Fernanda Godoy Rocha; Frank C Gibson; Jorge Frias-Lopez
Journal:  mSystems       Date:  2020-09-29       Impact factor: 6.496

2.  The Galleria mellonella larvae as an in vivo model for evaluation of Shigella virulence.

Authors:  Shoshana Barnoy; Hanan Gancz; Yuewei Zhu; Cary L Honnold; Daniel V Zurawski; Malabi M Venkatesan
Journal:  Gut Microbes       Date:  2017-02-13

Review 3.  Inhibition of Lipopolysaccharide- and Lipoprotein-Induced Inflammation by Antitoxin Peptide Pep19-2.5.

Authors:  Lena Heinbockel; Günther Weindl; Guillermo Martinez-de-Tejada; Wilmar Correa; Susana Sanchez-Gomez; Sergio Bárcena-Varela; Torsten Goldmann; Patrick Garidel; Thomas Gutsmann; Klaus Brandenburg
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

4.  Innate Immune Responses of Galleria mellonella to Mycobacterium bovis BCG Challenge Identified Using Proteomic and Molecular Approaches.

Authors:  Masanori Asai; Gerard Sheehan; Yanwen Li; Brian D Robertson; Kevin Kavanagh; Paul R Langford; Sandra M Newton
Journal:  Front Cell Infect Microbiol       Date:  2021-02-09       Impact factor: 5.293

Review 5.  The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.

Authors:  Bee Ha Gan; Josephine Gaynord; Sam M Rowe; Tomas Deingruber; David R Spring
Journal:  Chem Soc Rev       Date:  2021-07-05       Impact factor: 54.564

6.  Peptide dendrimers as "lead compounds" for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies.

Authors:  Arianna Pompilio; Cristina Geminiani; Paolo Mantini; Thissa N Siriwardena; Ivan Di Bonaventura; Jean Louis Reymond; Giovanni Di Bonaventura
Journal:  Infect Drug Resist       Date:  2018-10-11       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.